Ercros, S.A (ECR) Fair Value & Analysis
Basic Materials · ES · Market cap €317M
Fair value as of: Jun 24, 2026
Analysis
Ercros, S.A (ECR) currently trades at €3.47, while our model-based Fair Value estimate is €2.41 — implying the stock looks roughly 30.4% overvalued today. We read business quality at 93/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Ercros, S.A., together with its subsidiaries, manufactures and sells chemical and pharmaceutical products in Spain and internationally. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmaceuticals. The company offers ammonia, caustic soda and potash, chlorine chloroisocyanurates, dichloroethane, ercrosbio, hydrochloric acid, hydrogen peroxide, polyvinyl chloride, potassium carbonate, PVC compounds, sodium chlorate, sodium chlorite, sodium hypochlorite, sulfuric acid, and vinyl chloride. It also provides dipentaerythritol, ercrosgreen + resins, formaldehyde, methanol, moulding compounds, paraformaldehyde, pentaerythritol, and sodium formate. In addition, the company offers generic active pharmaceutical ingredients, including amlodipine besylate, azithromycin, clarithromycin, erythromycin, famotidine, fosfomycin, and fusidic acid, as well as customized production of antibiotics, anti-hypertensives, and anti-ulcer drugs. It exports its products.…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Ercros, S.A (ECR) undervalued?
What is the fair value of ECR?
What is the quality score of ECR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.